

BÖLÜM 16



KALP YETERSİZLİĞİNDE KULLANILAN DİĞER İLAÇLAR

Bahri KÖROĞLU¹

İVABRADİN

İvabradin ; stabil göğüs ağrısı ve kalp yetmezliğinin semptomatik tedavisinde kullanılan bir If inhibitörüdür. Kalp yetmezliğine bağlı semptomları olan ve kalp yetmezliğinin kötüleşmesi nedeniyle hastaneye yatma riskini azaltmak için EF %35 veya daha az ejeksiyon fraksiyonu olan hastalarda kullanım için onay almıştır. Kalp yetmezliği için İvabradin kullanımına uygun hastalar, düşük ejeksiyon hacmi ve kalp hızı en az 70 bpm olan semptomatik kalp yetmezliği olan ve durumu beta blokerler tarafından tam olarak yönetilemeyen hastalardır.^{1,2}

İvabradin, kalp hızını düzenleyen, sinoatrial nod ta bulunan, pacemaker özelliği olan hücrelerde If kanalını bloke eder. Buda kalp hızının azalmasına ve diyastolik sürenin uzamasına neden olur.³ Dinlenme anında kalp hızının yüksek olması, sol ventrikül fonksiyonlarına zararlı etkilere ve diyastol süresinin kısalması nedeniyle kalbe kan akımının azalmasına yol açabilir. Kalp hızının yüksek olması kardiyovasküler hastalığı olan hastalarda olumsuz sonuçlarla ilişkilendirilmiştir. Bu nedenle, kardiyovasküler morbidite ve mortaliteyi azaltmak için istirahat kalp atış hızını azaltmak, ilaç üreticileri arasında terapötik bir hedefdir. İvabradin kalp hızını azaltır ancak beta blokerler gibi miyokardiyal kasılma, gevşeme veya ventriküler repolarizasyonu etkilemez.

İvabradin ağızdan alınan tabletler şeklinde kullanılır.

- Başlangıç dozu günde iki kez 5 mg olmalıdır.
- Doz, kalp atış hızına göre 2 hafta sonra ayarlanabilir.

¹ Uzm. Dr., Sivas Numune Hastanesi, Kardiyoloji Bölümü, drbahrik@hotmail.com

KAYNAKLAR

1. Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. *Circulation journal : official journal of the Japanese Circulation Society*. 2019;83(2):252-60.
2. Krajcirovicova K, Aziriova S, Baka T, Repova K, Adamcova M, Paulis L, et al. Ivabradine does not impair anxiety-like behavior and memory in both healthy and L-NAME-induced hypertensive rats. *Physiological research*. 2018;67(Suppl 4):S655-s64.
3. Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ, et al. Anti-anginal drugs: Systematic review and clinical implications. *International journal of cardiology*. 2019;283:55-63.
4. Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. *Therapeutic advances in chronic disease*. 2018;9(11):199-207.
5. Ennezat PV, Le Jemtel T, Cosgrove S, Hallas J, Hansen MR. Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. *Acta cardiologica*. 2020;75(1):10-9.
6. Hartmann C, Bosch NL, de Aragão Miguita L, Tierie E, Zytinski L, Baena CP. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. *International journal of clinical pharmacy*. 2018;40(6):1443-53.
7. Osmanska J, Jhund PS. Contemporary Management of Heart Failure in the Elderly. *Drugs & aging*. 2019;36(2):137-46.
8. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *The New England journal of medicine*. 2020;382(20):1883-93.
9. Boettcher M, Gerisch M, Lobmeyer M, Besche N, Thomas D, Gerrits M, et al. Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. *Clinical pharmacokinetics*. 2020;59(11):1407-18.
10. Iacoviello M, Palazzuoli A, Gronda E. Recent advances in pharmacological treatment of heart failure. *European journal of clinical investigation*. 2021;51(11):e13624.
11. Ruehs H, Klein D, Frei M, Grevel J, Austin R, Becker C, et al. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *Clinical pharmacokinetics*. 2021;60(11):1407-21.
12. Sandner P, Vakalopoulos A, Hahn MG, Stasch JP, Follmann M. Soluble guanylate cyclase stimulators and their potential use: a patent review. *Expert opinion on therapeutic patents*. 2021;31(3):203-22.
13. Alsumali A, Lautsch D, Liu R, Patel D, Nanji S, Djatche LM. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event. *Advances in therapy*. 2021;38(5):2631-43.
14. Ezekowitz JA, O'Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. *JACC Heart failure*. 2020;8(11):931-9.
15. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. *Pharmacology & therapeutics*. 2009;122(3):216-38.
16. Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. *Jama*. 2020;324(15):1512-21.
17. Burnett JC, Jr. Vericiguat - Another Victory for Targeting Cyclic GMP in Heart Failure. *The New England journal of medicine*. 2020;382(20):1952-3.
18. Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. *European journal of clinical pharmacology*. 2021;77(4):527-37.
19. Murphy SP, Ibrahim NE, Januzzi JL, Jr. Heart Failure With Reduced Ejection Fraction: A Review. *Jama*. 2020;324(5):488-504.

20. Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. *European journal of heart failure*. 2021;23(8):1313-21.
21. Lang NN, Dobbin SJH, Petrie MC. Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. *Cardiovascular research*. 2020;116(12):e152-e5.
22. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. *European heart journal*. 2017;38(15):1119-27.
23. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part I. *Clinical pharmacokinetics*. 1998;34(6):457-82.
24. Ferdinand KC, Elkayam U, Mancini D, Ofili E, Piña I, Anand I, et al. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. *The American journal of cardiology*. 2014;114(1):151-9.
25. McComb MN, Chao JY, Ng TM. Direct Vasodilators and Sympatholytic Agents. *Journal of cardiovascular pharmacology and therapeutics*. 2016;21(1):3-19.
26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2013;128(16):e240-327.
27. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *Hypertension (Dallas, Tex : 1979)*. 2015;65(6):1372-407.
28. Riddiough MA. Preventing, detecting and managing adverse reactions of antihypertensive agents in the ambulant patient with essential hypertension. *American journal of hospital pharmacy*. 1977;34(5):465-79.
29. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. *Current opinion in rheumatology*. 2018;30(5):490-7.
30. Mahfouz A, Mahmoud AN, Ashfaq PA, Siyabi KH. A case report of hydralazine-induced skin reaction: Probable toxic epidermal necrolysis (TEN). *The American journal of case reports*. 2014;15:135-8.